Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer

Dr Simon Chowdhury - Guy's Hospital, London, UK

Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer ( Dr Simon Chowdhury - Guy's Hospital, London, UK )

Screening to identify unsuitable candidates for ipilimumab in advanced melanoma

Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy

Screening to identify unsuitable candidates for ipilimumab in advanced melanoma ( Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy )

Nivolumab alone superior to ipilimumab alone in advanced melanoma

Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy

Nivolumab alone superior to ipilimumab alone in advanced melanoma ( Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy )

New dexamethasone combination yields two-fold improvement in median PFS in...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

New dexamethasone combination yields two-fold improvement in median PFS in multiple myeloma ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma

Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )

ASCO 2015: Latest developments in multiple myeloma

Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos

ASCO 2015: Latest developments in multiple myeloma ( Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos )

Randomised trial of pembrolizumab versus standard treatment in patients with...

Dr Kevin Harrington - Institute of Cancer Research, London, UK

Randomised trial of pembrolizumab versus standard treatment in patients with recurrent or metastatic head and neck cancer ( Dr Kevin Harrington - Institute of Cancer Research, London, UK )

Adjuvant denosumab may preserve bone health in postmenopausal breast cancer...

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Adjuvant denosumab may preserve bone health in postmenopausal breast cancer patients: results of the ABCSG-18 trial ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )

ASCO 2015: Latest in chronic lymphocytic leukaemia

Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos

ASCO 2015: Latest in chronic lymphocytic leukaemia ( Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos )

Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma

Dr James Larkin - Royal Marsden Hospital, London, UK

Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma ( Dr James Larkin - Royal Marsden Hospital, London, UK )

Initial nivolumab-based treatment halts melanoma progression

Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Initial nivolumab-based treatment halts melanoma progression ( Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

New intelligence network that supports efforts to improve quality of care and...

Dr Allen Lichter, Chief Executive Officer, ASCO, USA

New intelligence network that supports efforts to improve quality of care and development of new medicines ( Dr Allen Lichter, Chief Executive Officer, ASCO, USA )

More from ecancer